Provectus Pharmaceuticals Inc. Completes Patient Accrual and Treatment for Phase 1 Trial of PV-10 for Liver Cancer
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.